Liquidia Technologies: Strong Market Position and Growth Potential Amid Legal Clarity and Strategic Advancements

Analyst Julian Harrison from BTIG maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) and keeping the price target at $37.00.

Julian Harrison has given his Buy rating due to a combination of factors that highlight Liquidia Technologies’ strong market position and growth potential. A significant legal risk was mitigated when the court denied United Therapeutics’ requests, which bodes well for Liquidia’s prospects in ongoing litigation. This legal clarity is expected to positively impact Liquidia’s final judgment outcomes, enhancing investor confidence.
Furthermore, Liquidia is on track to achieve profitability within the next three to four quarters, supported by the strategic detailing of YUTREPIA, which has received full FDA approval for PH-ILD and PAH. The competitive pricing and favorable dosing regimen of YUTREPIA, along with its lower royalty obligations compared to competitors, position it well in the market. Additionally, the large market opportunity in PH-ILD, with significant unmet needs, offers substantial growth potential for Liquidia, making it an attractive investment opportunity.

In another report released today, Needham also maintained a Buy rating on the stock with a $32.00 price target.